Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Am J Med Sci ; 361(3): 303-309, 2021 03.
Article in English | MEDLINE | ID: mdl-33268053

ABSTRACT

BACKGROUND: Cardiac troponin (cTn) is mainly used to diagnose acute coronary syndrome (ACS). However, cTn can also be elevated in critically ill patients secondary to demand ischemia or myocardial injury. The impact of cardiology consultation on the clinical outcomes of patients admitted to medical intensive care unit (ICU) with elevated cTn is unclear. METHODS: A retrospective analysis of medical ICU patients with elevated cTn without evidence of ACS between January 2013 through December 2018. Patients were stratified based on documentation of cardiology consultation. The primary outcome was 1-year mortality. Secondary outcomes were in-hospital and 30-day mortality, the length of stay (LOS), further cardiac testing, 30-day readmission rate, new prescription of cardiac medications, and the predictors of a cardiology consultation. RESULTS: Of 846 patients screened, 766 patients were included, of whom 63.2% had cardiology consultation. Cardiology consultation group had longer median LOS (7 vs. 5 days, P = 0.007), additional cardiac testing (90.3% vs. 67.7%, P < 0.001), and more new cardiac medications (52.1% vs. 16.3%, P < 0.001). No difference was noted in-hospital mortality (adjusted odds ratio [aOR], 0.6, 95% CI, 0.4-1.1, P = .117), 30-day mortality (aOR = 0.8, 95% CI, 0.5-1.4, P = .425), 1- year mortality (aOR, 1.4, 95% CI, 0.9-2.2, P = .193), or cardiac-specific 30-day readmission rate (aOR, 7.0, 95% CI, 0.7-14.9, P = .137). History of coronary artery disease (CAD) was the most independent predictor for a cardiology consult (aOR, 2.2, 95% CI, 1.3-3.8, P < .001). CONCLUSION: Cardiology consultation for elevated cTn in medical ICU patients was associated with increased cardiac testing and LOS, without significant impact on mortality.


Subject(s)
Acute Coronary Syndrome/etiology , Intensive Care Units/statistics & numerical data , Outcome and Process Assessment, Health Care/statistics & numerical data , Referral and Consultation/statistics & numerical data , Troponin/metabolism , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/metabolism , Acute Coronary Syndrome/mortality , Aged , Aged, 80 and over , Cardiology , Female , Humans , Male , Middle Aged , Nebraska , Retrospective Studies
2.
J Intensive Care Med ; 33(11): 635-644, 2018 Nov.
Article in English | MEDLINE | ID: mdl-27913775

ABSTRACT

BACKGROUND: The role of B-type natriuretic peptide (BNP) is less understood in the risk stratification of patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), especially in patients with normal left ventricular ejection fraction (LVEF). METHODS: This retrospective study from 2008 to 2012 evaluated all adult patients with AECOPD having BNP levels and available echocardiographic data demonstrating LVEF ≥40%. The patients were divided into groups 1, 2, and 3 with BNP ≤ 100, 101 to 500, and ≥501 pg/mL, respectively. A subgroup analysis was performed for patients without renal dysfunction. Outcomes included need for and duration of noninvasive ventilation (NIV) and mechanical ventilation (MV), NIV failure, reintubation at 48 hours, intensive care unit (ICU) and total length of stay (LOS), and in-hospital mortality. Two-tailed P < .05 was considered statistically significant. RESULTS: Of the total 1145 patients, 550 (48.0%) met our inclusion criteria (age 65.1 ± 12.2 years; 271 [49.3%] males). Groups 1, 2, and 3 had 214, 216, and 120 patients each, respectively, with higher comorbidities and worse biventricular function in higher categories. Higher BNP values were associated with higher MV use, NIV failure, MV duration, and ICU and total LOS. On multivariate analysis, BNP was an independent predictor of higher NIV and MV use, NIV failure, NIV and MV duration, and total LOS in groups 2 and 3 compared to group 1. B-type natriuretic peptide continued to demonstrate positive correlation with NIV and MV duration and ICU and total LOS independent of renal function in a subgroup analysis. CONCLUSION: Elevated admission BNP in patients with AECOPD and normal LVEF is associated with worse in-hospital outcomes and can be used to risk-stratify these patients.


Subject(s)
Natriuretic Peptide, Brain/blood , Patient Outcome Assessment , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/physiopathology , Ventricular Function, Left , Aged , Biomarkers/blood , Critical Care , Disease Progression , Female , Hospital Mortality , Humans , Kidney/physiopathology , Length of Stay , Male , Middle Aged , Noninvasive Ventilation , Pulmonary Disease, Chronic Obstructive/mortality , Pulmonary Disease, Chronic Obstructive/therapy , Respiration, Artificial , Retrospective Studies , Risk Assessment/methods , Time Factors
3.
WMJ ; 116(1): 37-9, 2017 02.
Article in English | MEDLINE | ID: mdl-29099568

ABSTRACT

INTRODUCTION: Levamisole-induced pseudovasculitis should be considered in patients with inconsistent anti-neutrophil cytoplasmic antibodies (ANCA) pattern and history of cocaine use. CASE PRESENTATION: A 50-year-old man presented to the emergency department with symptoms of bilateral pulmonary emboli. His hospital course was complicated by multiple end organ failure, which improved dramatically with prednisone. Although he was diagnosed previously with granulomatosis with polyangiitis due to positive proteinase 3 (PR3), myeloperoxidase (MPO), perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) and cytoplasmic anti-neutrophil cytoplasmic antibodies (C-ANCA) markers, his longstanding cocaine use and history of skin ulcers, thrombotic events, and febrile illnesses suggested a diagnosis of levamisole-induced pseudovasculitis instead. DISCUSSION: Differentiating between vasculitides can be challenging due to similar clinical and laboratory findings. To differentiate the two, biopsies should be obtained. The absence of granulomas or leukocytoclasia, and the presence of vasculopathic purpura, should guide clinicians toward pseudovasculitis. CONCLUSION: It is important to maintain a high index of suspicion for pseudovasculitis because long-term corticosteroid use to treat granulomatosis with polyangiitis can lead to detrimental effects.


Subject(s)
Antirheumatic Agents/poisoning , Cocaine-Related Disorders/complications , Levamisole/poisoning , Vasculitis/chemically induced , Acidosis/complications , Acute Kidney Injury/complications , Biomarkers/analysis , Diagnosis, Differential , Heart Failure/complications , Humans , Male , Middle Aged , Pneumonia/complications , Pulmonary Embolism/complications , Vasculitis/diagnosis
5.
BMJ Case Rep ; 20152015 Nov 03.
Article in English | MEDLINE | ID: mdl-26531738

ABSTRACT

Right-sided infective endocarditis (RIE) is commonly due to Staphylococcus aureus and often involves the tricuspid valve (TV). A 31-year-old man with prior intravenous drug use presented with substernal pain, cough, dyspnoea and fever. Examination revealed a febrile, tachycardic male with peripheral infective endocarditis stigmata and right-heart failure. Laboratory parameters demonstrated leucocytosis, lactic acidosis and methicillin-resistant S. aureus (MRSA) bacteraemia. Echocardiography demonstrated multiple TV echodensities and chest imaging confirmed septic emboli. The MRSA species demonstrated 'vancomycin-creep', necessitating therapy with daptomycin and ceftaroline. Owing to persistent bacteraemia and septic shock, the patient underwent TV surgery, but continued to have a poor postoperative course with subsequent death. Indications for surgical therapy of RIE are limited to the European guidelines and most data are extrapolated from left-heart disease. MRSA exhibiting vancomycin-creep portends a poorer prognosis and requires aggressive therapy. We advocate the use of ceftaroline salvage therapy with daptomycin, pending further trials.


Subject(s)
Endocarditis, Bacterial/microbiology , Heart Valve Diseases/microbiology , Methicillin-Resistant Staphylococcus aureus/drug effects , Mitral Valve , Staphylococcal Infections/drug therapy , Tricuspid Valve , Adult , Anti-Bacterial Agents/therapeutic use , Cephalosporins/therapeutic use , Daptomycin/therapeutic use , Drug Resistance, Multiple, Bacterial , Fatal Outcome , Humans , Male , Staphylococcal Infections/complications , Vancomycin/pharmacology , Ceftaroline
6.
BMJ Case Rep ; 20152015 Aug 26.
Article in English | MEDLINE | ID: mdl-26311008

ABSTRACT

Pneumocystis jirovecii is responsible for P. jirovecii pneumonia (PJP) in immunocompromised individuals, with a recent rise of cases noted in non-HIV patients. A middle-aged man presented with new-onset cough, fever, hypoxia and tachypnoea. He was on a tapering course of dexamethasone for amiodarone-induced thyrotoxicosis. He developed worsening airspace disease necessitating mechanical ventilation. Bronchoalveolar lavage (BAL) fluid was positive for P. jirovecii and he was managed with trimethoprim/sulfamethoxazole and pentamidine, but succumbed to cardiorespiratory arrest. One-third of PJP cases occur in non-HIV patients, and have a higher morbidity and mortality. Most immunocompromised patients typically exhibit PJP during a corticosteroid taper. The accurate dose, duration or frequency of steroid use in not well established. Diagnosis of PJP in this population is more challenging due to lower BAL yield with alternate modalities such as serum/BAL ß-d-glucan and PCR enhancing the yield. Further studies are needed to highlight PJP prophylaxis in patients with steroid use.


Subject(s)
HIV Infections , Lung/microbiology , Pneumocystis carinii , Pneumonia, Pneumocystis/immunology , Bronchoalveolar Lavage Fluid/microbiology , Fatal Outcome , HIV Infections/complications , Humans , Immunocompromised Host , Male , Middle Aged , Pneumonia, Pneumocystis/drug therapy , Pneumonia, Pneumocystis/microbiology , Polymerase Chain Reaction , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
7.
Case Rep Cardiol ; 2015: 927438, 2015.
Article in English | MEDLINE | ID: mdl-26075108

ABSTRACT

Amiodarone is reported to cause a wide continuum of serious clinical effects. It is often challenging to detect Amiodarone-induced pulmonary toxicity (AIPT). Typically, the diagnosis is made based on the clinical settings and may be supported by histopathology results, if available. We describe a 57-year-old patient who developed severe rapidly progressive respiratory failure secondary to AIPT with acute bilateral infiltrates and nodular opacities on chest imaging. Interestingly, Amiodarone was discontinued 3 weeks prior to his presentation. He had normal cardiac filling pressures confirmed by echocardiography. To our knowledge, this is the first case of isolated acute lung injury induced by Amiodarone, three weeks after therapy cessation, with adequate clinical improvement after supportive management and high dose steroid therapy.

SELECTION OF CITATIONS
SEARCH DETAIL
...